Gilead Sciences Inc. closed 1.35% below its 52-week high of $106.69, which the company achieved on February 14th.
A driver has serious injuries following a rollover crash on Gilead Street in Hebron Monday, state police said. State police ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
GlobalData on MSN5d
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP useLenacapavir is already approved under the name Sunlenca as an HIV treatment for patients resistant to other medication ...
A common CV risk factor calculator for patients with HIV underestimates risk for Black patients and women, while risk for ...
Assembly Bio said that it plans to advance ABI-1179 directly into the Phase 1b portion of the study, which will include ...
MarketBeat on MSN2d
Gilead Sciences: 4 Reasons This Stock Has Much More To RiseCompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...
Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. | Revenues in the biopharma industry continued to boom ...
Fintel on MSN5d
Deutsche Bank Upgrades Gilead Sciences (GILD)Fintel reports that on February 18, 2025, Deutsche Bank upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Hold ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback